Market Research Logo

Major Depressive Disorder - Pipeline Review, H2 2015

Major Depressive Disorder - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Major Depressive Disorder - Pipeline Review, H2 2015’, provides an overview of the Major Depressive Disorder’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Major Depressive Disorder
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Major Depressive Disorder and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Major Depressive Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Major Depressive Disorder pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Major Depressive Disorder Overview
Therapeutics Development
Pipeline Products for Major Depressive Disorder - Overview
Pipeline Products for Major Depressive Disorder - Comparative Analysis
Major Depressive Disorder - Therapeutics under Development by Companies
Major Depressive Disorder - Therapeutics under Investigation by Universities/Institutes
Major Depressive Disorder - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Major Depressive Disorder - Products under Development by Companies
Major Depressive Disorder - Products under Investigation by Universities/Institutes
Major Depressive Disorder - Companies Involved in Therapeutics Development
Aequus Pharmaceuticals Inc.
Alkermes Plc
Allergan Plc
Angelini Group
Azevan Pharmaceuticals, Inc.
BioCrea GmbH
Bristol-Myers Squibb Company
Cerecor Inc.
e-Therapeutics Plc
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
H. Lundbeck A/S
Hua Medicine Ltd.
Intra-Cellular Therapies, Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Johnson & Johnson
Lead Discovery Center GmbH
Luye Pharma Group Ltd.
Mapreg S.A.S.
Methylation Sciences Inc.
miCure Therapeutics Ltd.
Mitsubishi Tanabe Pharma Corporation
Naurex, Inc.
Neuralstem, Inc.
nLife Therapeutics, S.L.
Otsuka Holdings Co., Ltd.
Pherin Pharmaceuticals, Inc.
Reviva Pharmaceuticals Inc.
Richter Gedeon Nyrt.
Saniona AB
Sumitomo Dainippon Pharma Co., Ltd.
Sunovion Pharmaceuticals Inc.
Suven Life Sciences Ltd.
VistaGen Therapeutics, Inc.
Major Depressive Disorder - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(aripiprazole + sertraline) - Drug Profile
(samidorphan + buprenorphine hydrochloride) - Drug Profile
AN-788 - Drug Profile
aripiprazole - Drug Profile
AV-101 - Drug Profile
AVP-786 - Drug Profile
basimglurant - Drug Profile
brexpiprazole - Drug Profile
bupropion hydrochloride ER - Drug Profile
cariprazine - Drug Profile
CERC-301 - Drug Profile
CERC-501 - Drug Profile
desvenlafaxine succinate SR - Drug Profile
edivoxetine hydrochloride - Drug Profile
esketamine hydrochloride - Drug Profile
ITI-007 - Drug Profile
JNJ-42165279 - Drug Profile
JNJ-42847922 - Drug Profile
lurasidone hydrochloride - Drug Profile
LY-03005 - Drug Profile
LY-2940094 - Drug Profile
MAP-4343 - Drug Profile
MIN-117 - Drug Profile
miR-135 - Drug Profile
MSI-195 - Drug Profile
NLF-NEU - Drug Profile
NP-11948 - Drug Profile
NRX-1074 - Drug Profile
NSI-189 - Drug Profile
onabotulinumtoxin A - Drug Profile
PH-10 - Drug Profile
rapastinel - Drug Profile
RP-5063 - Drug Profile
SEP-363856 - Drug Profile
sirukumab - Drug Profile
Small Molecule to Inhibit FKBP51 for Major Depressive Disorder - Drug Profile
Small Molecule to Target SLC6A15 for Major Depressive Disorder - Drug Profile
Small Molecules to Agonize Kappa Opiod Receptors for Mania and Depressive disorders - Drug Profile
Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile
Small Molecules to Antagonize NMDA Receptor 2B for Depression and Major Depressive Disorder - Drug Profile
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile
SNG-11 - Drug Profile
SRX-246 - Drug Profile
SUVN-911 - Drug Profile
tedatioxetine hydrobromide - Drug Profile
tramadol hydrochloride - Drug Profile
trazodone hydrochloride - Drug Profile
vortioxetine hydrobromide - Drug Profile
VU-0431316 - Drug Profile
Major Depressive Disorder - Recent Pipeline Updates
Major Depressive Disorder - Dormant Projects
Major Depressive Disorder - Discontinued Products
Major Depressive Disorder - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Major Depressive Disorder, H2 2015
Number of Products under Development for Major Depressive Disorder - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015
Major Depressive Disorder - Pipeline by Aequus Pharmaceuticals Inc., H2 2015
Major Depressive Disorder - Pipeline by Alkermes Plc, H2 2015
Major Depressive Disorder - Pipeline by Allergan Plc, H2 2015
Major Depressive Disorder - Pipeline by Angelini Group, H2 2015
Major Depressive Disorder - Pipeline by Azevan Pharmaceuticals, Inc., H2 2015
Major Depressive Disorder - Pipeline by BioCrea GmbH, H2 2015
Major Depressive Disorder - Pipeline by Bristol-Myers Squibb Company, H2 2015
Major Depressive Disorder - Pipeline by Cerecor Inc., H2 2015
Major Depressive Disorder - Pipeline by e-Therapeutics Plc, H2 2015
Major Depressive Disorder - Pipeline by Eli Lilly and Company, H2 2015
Major Depressive Disorder - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Major Depressive Disorder - Pipeline by GlaxoSmithKline Plc, H2 2015
Major Depressive Disorder - Pipeline by H. Lundbeck A/S, H2 2015
Major Depressive Disorder - Pipeline by Hua Medicine Ltd., H2 2015
Major Depressive Disorder - Pipeline by Intra-Cellular Therapies, Inc., H2 2015
Major Depressive Disorder - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2015
Major Depressive Disorder - Pipeline by Johnson & Johnson, H2 2015
Major Depressive Disorder - Pipeline by Lead Discovery Center GmbH, H2 2015
Major Depressive Disorder - Pipeline by Luye Pharma Group Ltd., H2 2015
Major Depressive Disorder - Pipeline by Mapreg S.A.S., H2 2015
Major Depressive Disorder - Pipeline by Methylation Sciences Inc., H2 2015
Major Depressive Disorder - Pipeline by miCure Therapeutics Ltd., H2 2015
Major Depressive Disorder - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
Major Depressive Disorder - Pipeline by Naurex, Inc., H2 2015
Major Depressive Disorder - Pipeline by Neuralstem, Inc., H2 2015
Major Depressive Disorder - Pipeline by nLife Therapeutics, S.L., H2 2015
Major Depressive Disorder - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Major Depressive Disorder - Pipeline by Pherin Pharmaceuticals, Inc., H2 2015
Major Depressive Disorder - Pipeline by Reviva Pharmaceuticals Inc., H2 2015
Major Depressive Disorder - Pipeline by Richter Gedeon Nyrt., H2 2015
Major Depressive Disorder - Pipeline by Saniona AB, H2 2015
Major Depressive Disorder - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Major Depressive Disorder - Pipeline by Sunovion Pharmaceuticals Inc., H2 2015
Major Depressive Disorder - Pipeline by Suven Life Sciences Ltd., H2 2015
Major Depressive Disorder - Pipeline by VistaGen Therapeutics , Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Major Depressive Disorder Therapeutics - Recent Pipeline Updates, H2 2015
Major Depressive Disorder - Dormant Projects, H2 2015
Major Depressive Disorder - Dormant Projects (Contd...1), H2 2015
Major Depressive Disorder - Dormant Projects (Contd..2), H2 2015
Major Depressive Disorder - Dormant Projects (Contd..3), H2 2015
Major Depressive Disorder - Dormant Projects (Contd..4), H2 2015
Major Depressive Disorder - Dormant Projects (Contd..5), H2 2015
Major Depressive Disorder - Dormant Projects (Contd..6), H2 2015
Major Depressive Disorder - Discontinued Products, H2 2015
Major Depressive Disorder - Discontinued Products (Contd..1), H2 2015
Major Depressive Disorder - Discontinued Products (Contd..2), H2 2015
List of Figures
Number of Products under Development for Major Depressive Disorder, H2 2015
Number of Products under Development for Major Depressive Disorder - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report